Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
J Ros, M Rodríguez-Castells, N Saoudi… - Expert Review of …, 2023 - Taylor & Francis
Introduction The presence of a BRAF-V600E mutation in metastatic colorectal cancer
(mCRC) is observed in approximately 12% of cases and is associated with poor prognosis …
(mCRC) is observed in approximately 12% of cases and is associated with poor prognosis …
Oral Supramolecular Adsorbent for Preventing Chemo‐Induced Gastrointestinal Mucositis and Microbial Dysbiosis and for Enhancing Chemoimmunotherapy
The addition of immune checkpoint blockade (ICB) to cytotoxic chemotherapy has emerged
as the first‐line treatment for multiple cancers. Paradoxically, cytotoxic chemotherapy may …
as the first‐line treatment for multiple cancers. Paradoxically, cytotoxic chemotherapy may …
[HTML][HTML] Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis
L Guo, Y Wang, W Yang, C Wang, T Guo, J Yang… - Gastroenterology, 2023 - Elsevier
Background & Aims Tumor genetic testing is indispensable in the management of primary
and metastatic colorectal cancer (CRC), yet the indications for genomics-guided precision …
and metastatic colorectal cancer (CRC), yet the indications for genomics-guided precision …
[HTML][HTML] Progress of research on molecular targeted therapies for colorectal cancer
S Huang, J Ye, X Gao, X Huang, J Huang… - Frontiers in …, 2023 - frontiersin.org
Colorectal cancer (CRC) is one of the most common malignancies, accounting for
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …
[HTML][HTML] Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies
F Cheng, R Zhang, C Sun, Q Ran, C Zhang… - Frontiers in …, 2023 - frontiersin.org
Oxaliplatin-based chemotherapy is a standard treatment approach for colorectal cancer
(CRC). However, oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe dose …
(CRC). However, oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe dose …
[HTML][HTML] Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
G Mazzoli, R Cohen, S Lonardi, F Corti, E Elez… - European Journal of …, 2022 - Elsevier
Background Immune checkpoint inhibitors yielded unprecedented outcomes in patients with
mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal …
mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal …
[HTML][HTML] FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and≥ 3 circulating tumour cells: the …
E Aranda, JM Viéitez, A Gómez-España, SG Calle… - ESMO open, 2020 - Elsevier
ABSTRACT Purpose 5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus
bevacizumab is more effective than doublets plus bevacizumab as first-line therapy for …
bevacizumab is more effective than doublets plus bevacizumab as first-line therapy for …
[HTML][HTML] Progress in the application of immune checkpoint inhibitor-based immunotherapy for targeting different types of colorectal cancer
R He, Y Lao, W Yu, X Zhang, M Jiang, C Zhu - Frontiers in Oncology, 2021 - frontiersin.org
Colorectal cancer (CRC), a common malignant disease, has the second highest mortality
rate among all cancer types. Due to the diversity and heterogeneity of CRC, few effective …
rate among all cancer types. Due to the diversity and heterogeneity of CRC, few effective …
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal …
Introduction In patients with metastatic colorectal cancer (mCRC), baseline circulating
tumour DNA (ctDNA) variant allele fraction (VAF) might serve as a surrogate of disease …
tumour DNA (ctDNA) variant allele fraction (VAF) might serve as a surrogate of disease …
[HTML][HTML] Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
YL Tang, DD Li, JY Duan, LM Sheng… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is one of the most lethal and common malignancies in the world.
Chemotherapy has been the conventional treatment for metastatic CRC (mCRC) patients …
Chemotherapy has been the conventional treatment for metastatic CRC (mCRC) patients …